What is the recommended treatment for a patient with left femoral neck bone mineral density of 0.67 g/cm² and a T-score of –1.9?

Treatment Recommendation for T-score -1.9 (Osteopenia)

This patient with a T-score of -1.9 does not require pharmacologic treatment based on bone density alone, but should receive calcium and vitamin D supplementation, lifestyle modifications, and fracture risk assessment using FRAX to determine if treatment thresholds are met. 1

Classification and Initial Assessment

• A T-score of -1.9 at the left femoral neck falls within the osteopenia range (T-score between -1.0 and -2.5), not osteoporosis 1
• Osteopenia alone is not a disease requiring treatment and encompasses a wide range of fracture risks 2
• Treatment decisions must be based on absolute fracture risk, not just the T-score number 1

Fracture Risk Assessment Required

Calculate 10-year fracture probability using FRAX to determine if pharmacologic treatment is warranted 1:

• Treatment threshold: 10-year probability ≥20% for major osteoporotic fracture OR ≥3% for hip fracture 1
• FRAX incorporates: age, sex, BMI, prior fracture, parental hip fracture history, current smoking, glucocorticoid use, rheumatoid arthritis, secondary osteoporosis causes, and alcohol consumption 1
• If FRAX scores exceed these thresholds, pharmacologic therapy should be initiated despite T-score being above -2.5 1

Non-Pharmacologic Management (Mandatory for All)

All patients with osteopenia should receive the following interventions 1:

Calcium and Vitamin D Supplementation

• Calcium: 1,000-1,200 mg daily (dietary intake plus supplements if needed) 1
• Vitamin D: 800-1,000 IU daily minimum 1
• Target serum vitamin D level ≥20 ng/mL (50 nmol/L) 1

Lifestyle Modifications

• Weight-bearing and resistance exercise including balance training, flexibility exercises, and progressive strengthening 1
• Smoking cessation (smoking is an independent risk factor for osteoporosis) 1
• Limit alcohol consumption to reduce fracture risk 1

Pharmacologic Treatment Considerations

Bisphosphonates or other bone-modifying agents are indicated ONLY if 1:

• FRAX-calculated 10-year risk meets treatment thresholds (≥20% major osteoporotic fracture or ≥3% hip fracture) 1
• Patient has history of fragility fracture (even with T-score > -2.5) 1
• Patient is on chronic glucocorticoids (≥3 months) where treatment threshold is lower (T-score ≤-1.5 to -1.7) 1, 3, 4
• Patient has secondary causes of accelerated bone loss (aromatase inhibitors, androgen deprivation therapy, GnRH agonists, chronic inflammatory disease) 1

First-Line Pharmacologic Options (if indicated)

• Oral bisphosphonates: alendronate 70 mg weekly, risedronate 35 mg weekly, or ibandronate 150 mg monthly 1
• IV zoledronic acid: 5 mg annually for osteoporosis, 5 mg every 2 years for osteopenia 1
• Denosumab: 60 mg subcutaneously every 6 months (note: rebound fracture risk upon discontinuation requires bisphosphonate follow-up) 1

Follow-Up Monitoring

• Repeat DEXA in 1-2 years if T-score remains in osteopenic range without treatment 1
• More frequent monitoring (annually) if patient has risk factors for accelerated bone loss 1
• Reassess FRAX scores with updated BMD values 1

Critical Pitfalls to Avoid

• Do not treat based solely on T-score of -1.9 without calculating absolute fracture risk 1, 2
• Do not ignore fragility fractures: any low-trauma fracture warrants treatment consideration regardless of T-score 1
• Do not overlook secondary causes: evaluate for conditions causing accelerated bone loss (thyroid disease, malabsorption, hypogonadism, medications) 1, 4
• Do not forget that osteopenia label can cause unnecessary anxiety: focus counseling on modifiable risk factors and actual fracture probability 2